AZNCF News and Press, AstraZeneca Plc From 12/05/23

2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-11-30 16:55:30 ET Summary September-October, 2023, Barron’s, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery l...

2023-11-30 15:10:23 ET Summary AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline and potentially transforming its cancer care business. ImmunoGen's antibody drug conjugate, Elahere, is approved to treat ovarian cance...

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-11-27 15:07:58 ET Summary Virtus Artificial Intelligence & Technology Opportunities Fund (AIO) has added more AI and tech companies to its portfolio. However, the fund's performance has been relatively lackluster compared to its tech-oriented peers, as its differentiated ...

2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...

2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...

2023-11-19 09:56:29 ET Summary WisdomTree International Quality Dividend Growth Fund selects ex-North America dividend stocks with quality and expected earnings growth characteristics. The fund is well-diversified across countries, sectors, and holdings, with a focus on Europe. ...

2023-11-12 01:45:00 ET Summary Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO ...